Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial, page-127

Hi Scott, I just looked at the last neuro drug David Stamler took to approval and acquisition. That was AUSTEDO, a drug which added an atom to a drug already in use for control of Huntington's movement problems. The AUSTEDO tweak resulted in the drug which was 3 times a day now to twice a day. Teva wanted it and paid over $3billion to acquire Auspex. 1st quarter earnings for AUSTEDO in the US were reported this year to be $282million. Up 67% over 1st quarter 2023.
Back to ATH. When they talk about a possible $1B market for ATH434, that is a pretty big deal for a $21million market cap co. Good results from the double blind early stage 201 clinical trial could put a smile on everybody's face when they see the price action following those results. All IMHO. Just need a good 201 trial result. I haven't been following this closely. Have you seen much evidence to expect a better result from 201 over the recent 202 interim results?